Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

MXCT vs LNTH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MXCT
MaxCyte, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$93M
5Y Perf.-94.9%
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$5.92B
5Y Perf.+247.7%

MXCT vs LNTH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MXCT logoMXCT
LNTH logoLNTH
IndustryMedical - DevicesDrug Manufacturers - Specialty & Generic
Market Cap$93M$5.92B
Revenue (TTM)$33M$1.55B
Net Income (TTM)$-45M$279M
Gross Margin81.2%60.5%
Operating Margin-138.3%18.8%
Forward P/E17.5x
Total Debt$18M$738K
Cash & Equiv.$20M$359M

MXCT vs LNTHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MXCT
LNTH
StockJul 21May 26Return
MaxCyte, Inc. (MXCT)1005.1-94.9%
Lantheus Holdings, … (LNTH)100347.7+247.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: MXCT vs LNTH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LNTH leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
MXCT
MaxCyte, Inc.
The Specific-Use Pick

In this particular matchup, MXCT is outpaced on most metrics by others in the set.

Best for: healthcare exposure
LNTH
Lantheus Holdings, Inc.
The Income Pick

LNTH carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 0 yrs, beta 0.47
  • Rev growth 0.5%, EPS growth -21.8%, 3Y rev CAGR 18.1%
  • 41.9% 10Y total return vs MXCT's -94.9%
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthLNTH logoLNTH0.5% revenue growth vs MXCT's -14.5%
Quality / MarginsLNTH logoLNTH18.0% margin vs MXCT's -135.1%
Stability / SafetyLNTH logoLNTHBeta 0.47 vs MXCT's 1.44, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)LNTH logoLNTH+13.1% vs MXCT's -68.2%
Efficiency (ROA)LNTH logoLNTH12.4% ROA vs MXCT's -20.6%, ROIC 30.6% vs -18.7%

MXCT vs LNTH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MXCTMaxCyte, Inc.
FY 2024
Product
94.9%$21M
Product and Service, Other
5.1%$1M
LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M

MXCT vs LNTH — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLNTHLAGGINGMXCT

Income & Cash Flow (Last 12 Months)

LNTH leads this category, winning 5 of 6 comparable metrics.

LNTH is the larger business by revenue, generating $1.5B annually — 46.8x MXCT's $33M. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to MXCT's -135.1%. On growth, LNTH holds the edge at +1.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…
RevenueTrailing 12 months$33M$1.5B
EBITDAEarnings before interest/tax-$41M$347M
Net IncomeAfter-tax profit-$45M$279M
Free Cash FlowCash after capex-$36M$372M
Gross MarginGross profit ÷ Revenue+81.2%+60.5%
Operating MarginEBIT ÷ Revenue-138.3%+18.8%
Net MarginNet income ÷ Revenue-135.1%+18.0%
FCF MarginFCF ÷ Revenue-109.5%+24.0%
Rev. Growth (YoY)Latest quarter vs prior year-16.0%+1.2%
EPS Growth (YoY)Latest quarter vs prior year0.0%+76.5%
LNTH leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

MXCT leads this category, winning 3 of 3 comparable metrics.
MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…
Market CapShares × price$93M$5.9B
Enterprise ValueMkt cap + debt − cash$91M$5.6B
Trailing P/EPrice ÷ TTM EPS-2.08x26.69x
Forward P/EPrice ÷ next-FY EPS est.17.52x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple14.61x
Price / SalesMarket cap ÷ Revenue2.81x3.84x
Price / BookPrice ÷ Book value/share0.54x5.72x
Price / FCFMarket cap ÷ FCF16.73x
MXCT leads this category, winning 3 of 3 comparable metrics.

Profitability & Efficiency

LNTH leads this category, winning 8 of 8 comparable metrics.

LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-24 for MXCT. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MXCT's 0.10x. On the Piotroski fundamental quality scale (0–9), LNTH scores 5/9 vs MXCT's 2/9, reflecting solid financial health.

MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…
ROE (TTM)Return on equity-24.1%+24.3%
ROA (TTM)Return on assets-20.6%+12.4%
ROICReturn on invested capital-18.7%+30.6%
ROCEReturn on capital employed-22.2%+17.1%
Piotroski ScoreFundamental quality 0–925
Debt / EquityFinancial leverage0.10x0.00x
Net DebtTotal debt minus cash-$2M-$358M
Cash & Equiv.Liquid assets$20M$359M
Total DebtShort + long-term debt$18M$738,000
Interest CoverageEBIT ÷ Interest expense11.72x
LNTH leads this category, winning 8 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

LNTH leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $513 for MXCT. Over the past 12 months, LNTH leads with a +13.1% total return vs MXCT's -68.2%. The 3-year compound annual growth rate (CAGR) favors LNTH at -1.4% vs MXCT's -43.1% — a key indicator of consistent wealth creation.

MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…
YTD ReturnYear-to-date-43.8%+35.3%
1-Year ReturnPast 12 months-68.2%+13.1%
3-Year ReturnCumulative with dividends-81.6%-4.0%
5-Year ReturnCumulative with dividends-94.9%+314.2%
10-Year ReturnCumulative with dividends-94.9%+4192.5%
CAGR (3Y)Annualised 3-year return-43.1%-1.4%
LNTH leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

LNTH leads this category, winning 2 of 2 comparable metrics.

LNTH is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than MXCT's 1.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs MXCT's 30.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…
Beta (5Y)Sensitivity to S&P 5001.44x0.47x
52-Week HighHighest price in past year$2.86$93.00
52-Week LowLowest price in past year$0.66$47.25
% of 52W HighCurrent price vs 52-week peak+30.5%+97.8%
RSI (14)Momentum oscillator 0–10052.261.2
Avg Volume (50D)Average daily shares traded847K886K
LNTH leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricMXCT logoMXCTMaxCyte, Inc.LNTH logoLNTHLantheus Holdings…
Analyst RatingConsensus buy/hold/sellBuy
Price TargetConsensus 12-month target$101.00
# AnalystsCovering analysts17
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+0.2%+5.1%
Insufficient data to determine a leader in this category.
Key Takeaway

LNTH leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MXCT leads in 1 (Valuation Metrics).

Best OverallLantheus Holdings, Inc. (LNTH)Leads 4 of 6 categories
Loading custom metrics...

MXCT vs LNTH: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is MXCT or LNTH a better buy right now?

For growth investors, Lantheus Holdings, Inc.

(LNTH) is the stronger pick with 0. 5% revenue growth year-over-year, versus -14. 5% for MaxCyte, Inc. (MXCT). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — MXCT or LNTH?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to -94. 9% for MaxCyte, Inc. (MXCT). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus MXCT's -94. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — MXCT or LNTH?

By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.

(LNTH) is the lower-risk stock at 0. 47β versus MaxCyte, Inc. 's 1. 44β — meaning MXCT is approximately 206% more volatile than LNTH relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 10% for MaxCyte, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — MXCT or LNTH?

By revenue growth (latest reported year), Lantheus Holdings, Inc.

(LNTH) is pulling ahead at 0. 5% versus -14. 5% for MaxCyte, Inc. (MXCT). On earnings-per-share growth, the picture is similar: MaxCyte, Inc. grew EPS -7. 7% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — MXCT or LNTH?

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -135. 1% for MaxCyte, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus -138. 3% for MXCT. At the gross margin level — before operating expenses — MXCT leads at 81. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — MXCT or LNTH?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is MXCT or LNTH better for a retirement portfolio?

For long-horizon retirement investors, Lantheus Holdings, Inc.

(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Both have compounded well over 10 years (LNTH: +41. 9%, MXCT: -94. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between MXCT and LNTH?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

MXCT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 48%
Run This Screen
Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform MXCT and LNTH on the metrics below

Revenue Growth>
%
(MXCT: -16.0% · LNTH: 1.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.